Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
CARL
$12.84
$0.15
Carlsmed, Inc. develops and operates a surgical platform for the treatment of complex adult spinal deformities that enables surgeons to harness clinical intelligence, advanced image recognition, and 3D printing technologies. Its product includes aprevo, a medical platform that makes surgical plans and devices tailored to the precise medical situation of every individual patient. It provides New Technology Add-On Payment (NTAP) reimbursement. The company was incorporated in 2018 and is based in Carlsbad, California.
Next Earnings
2026-01-12
Beta
-0.20632373
Average Volume
72061.8
Market Cap
341452939
Last Dividend
0
CIK
0001794546
ISIN
US14280C1053
CUSIP
14280C105
CEO
Michael John Cordonnier
Sector
Healthcare
Industry
Medical - Healthcare Information Services
Full Time Employees
100
IPO Date
2018-04-05
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| Carlsmed Announces Preliminary Revenue for the Fourth Quarter and Full Year 2025 | Fourth quarter 2025 revenue of ~$15.2 million, representing ~61% growth over Q4 2024 Full Year 2025 revenue of ~$50.5 million; representing ~86% growth over 2024 | GlobeNewsWire | 2026-01-12 08:05:00 |
| Carlsmed, Inc.’s Lock-Up Period Set To End on January 19th (NASDAQ:CARL) | Carlsmed's (NASDAQ: CARL - Get Free Report) lock-up period will end on Monday, January 19th. Carlsmed had issued 6,700,000 shares in its initial public offering on July 23rd. The total size of the offering was $100,500,000 based on an initial share price of $15.00. After the end of the company's lock-up period, restrictions preventing major shareholders | Defense World | 2026-01-12 01:20:42 |
| Carlsmed aprevo® Lumbar 2-year Data Published in Global Spine Journal | CARLSBAD, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced the publication of a new retrospective cohort study in Global Spine Journal demonstrating that 3D preoperative planning combined with patient-specific, anatomically designed interbody implants significantly reduces mechanical complication–related reoperations in complex adult spinal deformity (ASD) surgery. | GlobeNewsWire | 2026-01-06 16:05:00 |
| Carlsmed, Inc. To Participate in the J.P. Morgan 2026 Healthcare Conference | CARLSBAD, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced that Mike Cordonnier, Chairman and CEO of Carlsmed will be presenting at the J.P. Morgan 2026 Healthcare conference on Wednesday, January 14th at 4:30-5:10 pm PT in San Francisco, CA. During the conference, Carlsmed Management will be hosting 1x1 investor meetings. | GlobeNewsWire | 2025-12-16 16:01:00 |
| CARL Launches Aprevo Cervical Platform for Personalized Spine Surgery | Carlsmed launches personalized aprevo cervical platform with early cases and new reimbursement support driving momentum in spine surgery. | Zacks Investment Research | 2025-12-09 08:31:08 |
| Carlsmed Announces U.S. Launch of its aprevo® Technology Platform for Cervical Fusion Surgeries at the Cervical Spine Research Society (CSRS) 53rd Annual Meeting | First 50+ cervical cases completed; observations on initial clinical experience to be presented by early adopters at the Carlsmed CSRS Lunch Workshop First 50+ cervical cases completed; observations on initial clinical experience to be presented by early adopters at the Carlsmed CSRS Lunch Workshop | GlobeNewsWire | 2025-12-03 07:00:00 |
| Carlsmed, Inc. To Participate in the Piper Sandler 37th Annual Healthcare Conference | CARLSBAD, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced that Mike Cordonnier, Chairman and CEO of Carlsmed, will be presenting at the 37th Annual Piper Sandler Healthcare conference on Wednesday, December 3rd at 9:00-9:25 am ET in New York, NY. During the conference, Carlsmed Management will be hosting 1x1 investor meetings. | GlobeNewsWire | 2025-11-19 16:01:00 |
| Carlsmed Reports Third Quarter 2025 Financial Results and Raises Full-Year Guidance | Third quarter revenue of $13.1 million, representing 98% growth YoY Raising full year 2025 revenue guidance to $49 million - $50 million CARLSBAD, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today reported financial results for the third quarter ended September 30, 2025. | GlobeNewsWire | 2025-11-06 16:01:00 |
| Carlsmed Inc. to Report Third Quarter 2025 Financial Results on November 6, 2025 | CARLSBAD, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced it will report its third quarter 2025 financial results after market close on Thursday, November 6, 2025. Management will also host a conference call and concurrent webcast starting at 1:30 PM Pacific Time. | GlobeNewsWire | 2025-10-23 16:01:00 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| 8-K | 2026-01-12 | 2026-01-12 | View Filing |
| SC 13G | 2025-11-14 | 2025-11-14 | View Filing |
| SC 13G | 2025-11-13 | 2025-11-13 | View Filing |
| 10-Q | 2025-11-06 | 2025-11-06 | View Filing |
| 8-K | 2025-11-06 | 2025-11-06 | View Filing |
| 8-K | 2025-10-30 | 2025-10-30 | View Filing |
| 10-Q | 2025-08-28 | 2025-08-28 | View Filing |
| 8-K | 2025-08-28 | 2025-08-28 | View Filing |
| 4 | 2025-07-24 | 2025-07-24 | View Filing |
| 4 | 2025-07-24 | 2025-07-24 | View Filing |
| 4 | 2025-07-24 | 2025-07-24 | View Filing |
| 4 | 2025-07-24 | 2025-07-24 | View Filing |
| 4 | 2025-07-24 | 2025-07-24 | View Filing |
| 4 | 2025-07-24 | 2025-07-24 | View Filing |
| 4 | 2025-07-24 | 2025-07-24 | View Filing |
| 4 | 2025-07-24 | 2025-07-24 | View Filing |
| 4 | 2025-07-24 | 2025-07-24 | View Filing |
| 4 | 2025-07-24 | 2025-07-24 | View Filing |
| 4 | 2025-07-24 | 2025-07-24 | View Filing |
| SC 13G | 2025-07-24 | 2025-07-24 | View Filing |
| 8-K | 2025-07-24 | 2025-07-24 | View Filing |
| S-8 | 2025-07-24 | 2025-07-24 | View Filing |
| 424B4 | 2025-07-24 | 2025-07-24 | View Filing |
| EFFECT | 2025-07-23 | 2025-07-23 | View Filing |
| 3 | 2025-07-22 | 2025-07-22 | View Filing |
| 3 | 2025-07-22 | 2025-07-22 | View Filing |
| 3 | 2025-07-22 | 2025-07-22 | View Filing |
| 3 | 2025-07-22 | 2025-07-22 | View Filing |
| 3 | 2025-07-22 | 2025-07-22 | View Filing |
| 3 | 2025-07-22 | 2025-07-22 | View Filing |
| 3 | 2025-07-22 | 2025-07-22 | View Filing |
| 3 | 2025-07-22 | 2025-07-22 | View Filing |
| 3 | 2025-07-22 | 2025-07-22 | View Filing |
| 3 | 2025-07-22 | 2025-07-22 | View Filing |
| 3 | 2025-07-22 | 2025-07-22 | View Filing |
| CERT | 2025-07-22 | 2025-07-22 | View Filing |
| 8-A12B | 2025-07-21 | 2025-07-21 | View Filing |
| CORRESP | 2025-07-18 | 2025-07-18 | View Filing |
| CORRESP | 2025-07-18 | 2025-07-18 | View Filing |
| CORRESP | 2025-07-15 | 2025-07-15 | View Filing |
| S-1/A | 2025-07-15 | 2025-07-15 | View Filing |
| CORRESP | 2025-07-07 | 2025-07-07 | View Filing |
| CORRESP | 2025-06-26 | 2025-06-26 | View Filing |
| S-1 | 2025-06-26 | 2025-06-26 | View Filing |
| UPLOAD | 2025-06-17 | 2025-06-17 | View Filing |
| DRSLTR | 2025-05-30 | 2025-05-30 | View Filing |
| DRS/A | 2025-05-30 | 2025-05-30 | View Filing |
| UPLOAD | 2025-05-21 | 2025-05-21 | View Filing |
| DRSLTR | 2025-04-23 | 2025-04-23 | View Filing |
| DRS | 2025-04-24 | 2025-04-23 | View Filing |
| D/A | 2025-02-07 | 2025-02-06 | View Filing |
| D | 2024-03-21 | 2024-03-21 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|